Moderna, Inc.(MRNA)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
MRNA | 59.43 B | -18.66x | 2.10% | -1.41% | $-7.98 | -39.00% | 0.19 | - | $176.66 | $22.28 |
BIIB | 33.17 B | 40.16x | 3.40% | 8.32% | $5.59 | 4.58% | 0.44 | - | $222.85 | $133.53 |
INSM | 27.66 B | -29.88x | 2.96% | -76.94% | $-4.24 | -87.22% | 0.98 | - | $212.75 | $90.39 |
INCY | 25.95 B | 16.31x | 37.70% | 27.71% | $7.85 | 30.67% | 0.60 | - | $132.60 | $81.09 |
UTHR | 21.03 B | 17.56x | -1.90% | 41.56% | $27.92 | 19.32% | - | - | $609.35 | $375.61 |
Peer Valuation & Performance Analysis
Peer group analysis for Moderna, Inc. (MRNA) compared to its primary competitors (including BIIB, INSM, INCY) reveals distinct metrics. MRNA trades at a valuation discount relative to its competitors, with a P/E ratio of -18.7x versus the peer average of 11.0x (representing a 269% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, MRNA's revenue growth of 2.1% lags behind the peer average of 10.5%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of -1.4% is comparable to the peer average of 0.2%.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• MRNA ranks #0 in P/E ratio, #4 in revenue growth, and #4 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $145.94 | $150.20 | $142.78 | $148.87 | 13,272,500 | +2.00% |
| 2026-09-02 | $151.40 | $156.41 | $146.54 | $150.81 | 16,563,200 | -0.39% |
| 2026-09-01 | $140.25 | $154.70 | $138.09 | $154.27 | 25,831,700 | +10.00% |
| 2026-08-31 | $134.10 | $144.20 | $133.85 | $140.34 | 18,570,700 | +4.65% |
| 2026-08-28 | $137.19 | $138.80 | $133.33 | $137.99 | 25,820,600 | +0.58% |
| 2026-08-27 | $144.18 | $148.59 | $138.54 | $142.77 | 24,993,200 | -0.98% |
| 2026-08-26 | $154.20 | $156.13 | $145.10 | $149.66 | 22,009,500 | -2.94% |
| 2026-08-25 | $143.50 | $161.37 | $141.21 | $158.83 | 49,225,700 | +10.68% |
| 2026-08-24 | $142.70 | $145.50 | $130.00 | $138.89 | 31,587,200 | -2.67% |
| 2026-08-21 | $133.11 | $159.47 | $132.42 | $145.13 | 87,316,100 | +9.03% |
| 2026-08-20 | $150.14 | $155.00 | $128.61 | $133.32 | 99,499,900 | -11.20% |
| 2026-08-19 | $116.02 | $176.66 | $114.46 | $174.38 | 195,334,600 | +50.30% |
| 2026-08-18 | $63.04 | $64.46 | $62.13 | $62.96 | 4,298,100 | -0.13% |
| 2026-08-17 | $64.78 | $65.53 | $62.91 | $64.46 | 3,979,600 | -0.49% |
| 2026-08-14 | $62.89 | $63.78 | $60.82 | $63.32 | 4,694,200 | +0.68% |
Explore More Analysis for MRNA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.